Ambrx Biopharma American Stock Shares Owned By Institutions
| AMAMDelisted Stock | USD 15.73 0.71 4.73% |
Ambrx Biopharma American fundamentals help investors to digest information that contributes to Ambrx Biopharma's financial success or failures. It also enables traders to predict the movement of Ambrx Stock. The fundamental analysis module provides a way to measure Ambrx Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ambrx Biopharma stock.
Ambrx |
Ambrx Biopharma American Company Shares Owned By Institutions Analysis
Ambrx Biopharma's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Ambrx Biopharma Shares Owned By Institutions | 97.91 % |
Most of Ambrx Biopharma's fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ambrx Biopharma American is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
CompetitionBased on the latest financial disclosure, 97% of Ambrx Biopharma American are shares owned by institutions. This is 119.33% higher than that of the Biotechnology sector and 106.13% higher than that of the Health Care industry. The shares owned by institutions for all United States stocks is 149.71% lower than that of the firm.
Ambrx Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ambrx Biopharma's direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ambrx Biopharma could also be used in its relative valuation, which is a method of valuing Ambrx Biopharma by comparing valuation metrics of similar companies.Ambrx Biopharma is currently under evaluation in shares owned by institutions category among its peers.
Ambrx Fundamentals
| Return On Equity | -0.37 | |||
| Return On Asset | -0.19 | |||
| Operating Margin | (483.51) % | |||
| Current Valuation | 1.56 B | |||
| Shares Outstanding | 63.29 M | |||
| Shares Owned By Insiders | 2.09 % | |||
| Shares Owned By Institutions | 97.91 % | |||
| Number Of Shares Shorted | 1.16 M | |||
| Price To Earning | 0.19 X | |||
| Price To Book | 7.31 X | |||
| Price To Sales | 432.96 X | |||
| Revenue | 4.09 M | |||
| Gross Profit | 7.4 M | |||
| EBITDA | (61.75 M) | |||
| Net Income | (67.06 M) | |||
| Cash And Equivalents | 110.89 M | |||
| Cash Per Share | 2.87 X | |||
| Total Debt | 11.98 M | |||
| Debt To Equity | 0.09 % | |||
| Current Ratio | 4.70 X | |||
| Book Value Per Share | 3.85 X | |||
| Cash Flow From Operations | (57.7 M) | |||
| Short Ratio | 1.21 X | |||
| Earnings Per Share | 0.42 X | |||
| Price To Earnings To Growth | (0.15) X | |||
| Target Price | 28.5 | |||
| Number Of Employees | 87 | |||
| Beta | -2.36 | |||
| Market Capitalization | 1.77 B | |||
| Total Asset | 146.98 M | |||
| Retained Earnings | (291.63 M) | |||
| Working Capital | 73.92 M | |||
| Z Score | 85.23 | |||
| Net Asset | 146.98 M |
About Ambrx Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ambrx Biopharma American's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ambrx Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ambrx Biopharma American based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Ambrx Stock
If you are still planning to invest in Ambrx Biopharma American check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ambrx Biopharma's history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |